3/24/99

K984062

8.0 510(k) Summary

510(k) Summary

(As required by 21 CFR 807.92)

A. Submitter Information

Submitter's Name:

Daig Corporation, a St. Jude Medical Company

Address:

14901 DeVeau Place

Minnetonka, Minnesota 55345-2126 U.S.A.

Telephone Number:

(612) 933-4700

Contact Person:

Todd J. Kornmann

Date Submission Prepared:

November 13, 1998

B. Device Information

Common or Usual Name:

Seal-AwayTM Hemostasis Adapter

Classification Name:

Introducer

Predicate Device:

Removable Hemostasis Adapter with Sideport

(K894343)

Device Description:

The Daig Seal-Away™ Hemostasis Adapter is an Introducer Accessory designed to provide easy access to the vascular system while providing convenient temporary closure of a standard indwelling introducer access site during

introduction of pacing leads, angiographic catheters,

closed and cameters, balloon catheters and

electrodes into a vessel.

Intended Use:

The Daig Seal-Away™ Hemostasis Adapter is designed to minimize the blood loss during the

introduction of angiographic catheters, closed end catheters, balloon catheters and electrodes into a

vessel. (same as predicate device)

C. Comparison of Required Technological Characteristics

8.0 510(k) Sumn	nary
-----------------	------

All technological characteristics of the Seal-Away™ Hemostasis Adapter are substantially equivalent to the predicate device (K894343) including product design, packaging, sterilization, and labeling.

D. Support of the Substantial Equivalence

Daig Corporation considers the Seal-AwayTM Hemostasis Adapter to be substantially equivalent to the following predicate device: the Removable Hemostasis Adapter with Sideport used with the Percutaneous Catheter Introducer which received marketing clearance on September 26, 1989 (K894343).



Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

MAR 2 4 1999

Mr. Todd Kornmann Senior Regulatory Affairs Specialist DAIG Corporation 14901 DeVeau Place Minnetonka, MN 55345-2126

Re: K984062

Trade Name: Seal-Away™ Hemostasis Adapter

Regulatory Class: II Product Code: DYB

Dated: February 18, 1999 Received: February 19, 1999

Dear Mr. Kornmann:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any

obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4586. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Thomas J. Callahan, Ph.D.

Director

Division of Cardiovascular, Respiratory And Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

		r	Page of	1
510(k) Number (if kn	own). K984	1062		
o ro(it) rtamber (ii iti)	11001			
Device Name:	Seal- Away	™ Hemostasis Ada	apter	
Indications for Use:				
catheters, close		oon catheters and ele	r the introduction of ang ectrodes into a vessel wh	
(PLEASE DO NOT V NEEDED)	VRITE BELOW TH	IIS LINE-CONTINU	JE ON ANOTHER PA	GE IF
Co	ncurrence of CDR	H, Office of Device	Evaluation (ODE)	
		(Division Sign-Off) Division of Cardiova and Neurological De		-
Prescription Use (Per 21 CFR 801.109	9)	510(k) Number	er-The-Counter Use (Optional Forma	it 1-2-96)